Viatris in talks to sell European OTC assets to CVC, Bloomberg says

Viatris is in talks to sell its European over-the-counter, or OTC, consumer-health assets to a company owned by buyout firm CVC Capital in a deal that could be valued at more than $2.1B, people familiar with the matter told Bloomberg’s Dinesh Nair, Aaron Kirchfeld and Manuel Baigorri. CVC’s over-the-counter drugmaker Cooper Consumer Health has emerged as “the most serious contender” for the assets after other suitors dropped out, but no final agreements have been reached, the report added.